Examination of bone mineral density in patients with varied liver diseases - a cross-sectional study

doi:10.4254/wjh.120697

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

(2)

(3)

(0)

(42)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Aug 27, 2026; 18(8): 120697
Published online Aug 27, 2026. doi: 10.4254/wjh.120697

Table 1 Patient demographics, median (interquartile range)

Group	n	Median age	Female	Male	BMI (kg/m²)	Liver function panel	MELD-score	Child-Pugh score	Bisphosphonate use
PBC	15	64 (57-72)	11	4	28	ALT: 68 (45-92) U/L	14 (11-17)	8 (7-9) (class B)	6
						γ-GT: 460 (320-590) U/L
						Bilirubin: 3.2 (2.1-4.8) mg/dL
PSC	22	49 (42-63)	7	15	22	ALT: 74 (50-108) U/L	-	7 (6-9) (class B)	3
						γ-GT: 410 (280-570) U/L
						Bilirubin: 2.8 (1.9-4.3) mg/dL
HCV	11	66 (64-75)	7	4	27	ALT: 74 (52-106) U/L	-	6 (5-7) (class A)	3
						γ-GT: 220 (150-310) U/L
						Bilirubin: 2.0 (1.3-3.1) mg/dL
AIH	13	63 (53-70)	10	3	26	ALT: 102 (84-155) U/L	-	7 (6-8) (class B)	2
						γ-GT: 310 (220-420) U/L
						Bilirubin: 2.5 (1.4-3.9) mg/dL
Cysts	21	57 (49-63)	18	3	24	ALT: 45 (30-60) U/L	-	5 (5-6) (class A)	1
						γ-GT: 110 (85-150) U/L
						Bilirubin: 0.9 (0.5-1.4) mg/dL
Control	101	50 (48-53)	16	85	27	Within normal range	-	-	-

Baseline demographic characteristics of patients with different etiologies of end-stage liver disease and healthy controls. PBC: Primary biliary cholangitis; PSC: Primary sclerosing cholangitis; HCV: Hepatitis C virus infection; AIH: Autoimmune hepatitis; Cysts: Hepatic cystic disease; Control: Healthy control group; BMI: Body mass index; MELD: Model of End-Stage Liver Disease; ALT: Alanin aminotransferase; γ-GT: Gamma-glutamyl transferase.

Full Size Table

Citation: Rohland O, Schwarzer L, Schwenk L, Pollmann N, Ali Deeb A, Settmacher U, Rauchfuss F, Dondorf F, Amrein K, Kocijan R, Ardelt M. Examination of bone mineral density in patients with varied liver diseases - a cross-sectional study. World J Hepatol 2026; 18(8): 120697
URL: https://www.wjgnet.com/1948-5182/full/v18/i8/120697.htm
DOI: https://dx.doi.org/10.4254/wjh.120697

Rohland O, Schwarzer L, Schwenk L, Pollmann N, Ali Deeb A, Settmacher U, Rauchfuss F, Dondorf F, Amrein K, Kocijan R, Ardelt M. Examination of bone mineral density in patients with varied liver diseases - a cross-sectional study. World J Hepatol 2026; 18(8): 120697 [DOI: 10.4254/wjh.120697]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.